GILD vs VIR: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. GILD and VIR share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined GILD and VIR exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Gilead Sciences is a large biopharmaceutical company best known for its leadership in treating viral diseases, especially HIV. Its HIV franchise, anchored by widely used single-tablet regimens like Biktarvy and the long-acting prevention drug for pre-exposure prophylaxis, generates the bulk of its revenue and is a global standard of care. Gilead also has a significant presence in liver diseases, including hepatitis B and C, where its cures transformed treatment, and in COVID-19 with the antiviral remdesivir. More recently, Gilead has expanded into oncology through acquisitions, building a portfolio in cell therapy (CAR-T) and antibody-drug conjugates for cancers such as breast and bladder cancer. The company makes money by selling these prescription medicines worldwide, supported by patents and strong pricing. Headquartered in Foster City, California, Gilead generates substantial cash flow from its HIV base, pays a solid dividend, and is investing to diversify into oncology and other areas as it manages future patent expirations.

Full GILD guide

Vir Biotechnology is a clinical-stage company applying immunology and antibody engineering to serious diseases. It built its reputation in infectious disease and has been reorienting toward oncology and chronic viral conditions. Its lead late-stage program is a combination therapy for chronic hepatitis delta, pairing the antibody tobevibart with the siRNA agent elebsiran, which has generated encouraging viral-suppression data in mid-stage studies and is advancing through registrational trials. Alongside this, Vir has been building an oncology franchise around its PRO-XTEN dual-masked T-cell-engager platform, designed to activate the immune system against tumors while limiting off-target toxicity, with early programs targeting indications such as prostate cancer.

Full VIR guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• GILD drivers: Dominant HIV franchise; Oncology expansion.
• VIR drivers: Chronic hepatitis delta combination as lead value driver; Oncology pivot via masked T-cell engagers.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Gilead is heavily dependent on its HIV franchise, so any new competition, pricing pressure, or patent expiration there is a major risk. For VIR, vir faces the classic risks of a clinical-stage biotech.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick GILD if you believe its drivers more; VIR if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the GILD and VIR guides.

GILD. Gilead is valued as a mature, cash-generative biopharma with a dominant HIV base and a solid dividend, rather than a high-growth name. Investors weigh durable virology cash flows and capital return against limited overall growth and uncertainty in oncology. Reported earnings can swing with acquisition-related charges, so investors often focus on underlying product revenue and free cash flow.

VIR. These are approximate, qualitative descriptions appropriate for a pre-revenue clinical-stage biotech, not precise financials. Cash balances, trial status, and runway estimates change with each quarter and each readout. Verify the latest cash position, pipeline milestones, and any financing activity against current filings and live data before acting.

Headline figures (approximate, early 2026): GILD shows revenue (ttm) ~$28 to 30 billion, operating margin ~thirties percent (varies with charges), net income (ttm) ~variable, affected by acquisition charges, dividend yield ~3 to 4%; VIR shows revenue Minimal recurring product revenue; as a clinical-stage company, income is driven mainly by collaboration, licensing, or milestone arrangements rather than product sales., profitability Operating at a loss, as is typical for a development-stage biotech investing heavily in clinical trials and research. Sustained profitability would depend on future approvals and commercialization., cash runway Backed by a sizeable cash and investments balance, extended by partnership and licensing deals, positioned to fund operations through several upcoming clinical catalysts. This is the key metric for a pre-revenue biotech., pipeline stage Lead hepatitis delta combination in registrational-stage development; oncology T-cell engagers in earlier Phase 1 dose-escalation. Value is concentrated in a handful of programs..

GILD and VIR are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined GILD and VIR exposure against your real portfolio. It is not an investment adviser.